Literature DB >> 25971363

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.

T P Vassilakopoulos1, G A Pangalis2, S Chatziioannou3, S Papageorgiou4, M K Angelopoulou1, Z Galani5, G Kourti6, V Prassopoulos7, T Leonidopoulou8, E Terpos9, M N Dimopoulou1, S Sachanas2, C Kalpadakis10, P Konstantinidou11, D Boutsis12, E Stefanoudaki13, L Kyriazopoulou14, M P Siakantaris15, M-C Kyrtsonis16, E Variami15, I Kotsianidis17, A Symeonidis18, E Michali19, E Katodritou11, G Kokkini8, C Tsatalas17, H Papadaki10, M-A Dimopoulos9, V Sotiropoulos20, V Pappa4, T Karmiris6, J Meletis1, J Apostolidis6, I Datseris21, P Panayiotidis16, K Konstantopoulos1, P Roussou5, P Rondogianni21.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25971363     DOI： 10.1038/leu.2015.120

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.

Authors:  Theodoros P Vassilakopoulos; Gerassimos A Pangalis; Andreas Katsigiannis; Sotirios G Papageorgiou; Nikos Constantinou; Evangelos Terpos; Alexandra Zorbala; Effimia Vrakidou; Panagiotis Repoussis; Christos Poziopoulos; Zacharoula Galani; Maria N Dimopoulou; Stella I Kokoris; Sotirios Sachanas; Christina Kalpadakis; Evagelia M Dimitriadou; Marina P Siakantaris; Marie-Christine Kyrtsonis; John Dervenoulas; Meletios A Dimopoulos; John Meletis; Paraskevi Roussou; Panayiotis Panayiotidis; Photis Beris; Maria K Angelopoulou
Journal:  Oncologist       Date:  2012-01-26

3.  Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.

Authors:  Michele Pohlen; Hans U Gerth; Ruediger Liersch; Steffen Koschmieder; Rolf M Mesters; Torsten Kessler; Iris Appelmann; Carsten Müller-Tidow; Wolfgang E Berdel
Journal:  Am J Hematol       Date:  2011-09-02       Impact factor: 10.047

4.  The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients.

Authors:  Pier Luigi Zinzani; Alessandro Broccoli; Beatrice Casadei; Vittorio Stefoni; Cinzia Pellegrini; Letizia Gandolfi; Roberto Maglie; Lisa Argnani; Stefano Pileri; Stefano Fanti
Journal:  Hematol Oncol       Date:  2014-09-25       Impact factor: 5.271

5.  The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

Authors:  Chan Y Cheah; Michael S Hofman; John F Seymour; David S Ritchie; Michael Dickinson; Andrew Wirth; H Miles Prince; Max Wolf; Elchanan H Januszcewicz; Dennis A Carney; Kirsten E Herbert; Simon J Harrison; Kate L Burbury; Constantine S Tam
Journal:  Leuk Lymphoma       Date:  2014-06-16

6.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

7.  Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.

Authors:  Andrea Riccardo Filippi; Cristina Piva; Francesca Giunta; Marilena Bellò; Annalisa Chiappella; Daniele Caracciolo; Michela Zotta; Anastasios Douroukas; Riccardo Ragona; Umberto Vitolo; Gianni Bisi; Umberto Ricardi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-02       Impact factor: 7.038

8.  Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.

Authors:  Jacob D Soumerai; Matthew D Hellmann; Yang Feng; Aliyah R Sohani; Christiana E Toomey; Jeffrey A Barnes; Ronald W Takvorian; Donna Neuberg; Ephraim P Hochberg; Jeremy S Abramson
Journal:  Leuk Lymphoma       Date:  2013-07-29

9.  The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.

Authors:  Abraham Avigdor; Tsvi Sirotkin; Meirav Kedmi; Elena Ribakovsy; Miriam Berkowicz; Yaron Davidovitz; Abraham Kneller; Drorit Merkel; Yulia Volchek; Tima Davidson; Elinor Goshen; Sara Apter; Avichai Shimoni; Isaac Ben-Bassat; Arnon Nagler
Journal:  Ann Hematol       Date:  2014-03-05       Impact factor: 3.673

10.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245
View more
  13 in total

1.  Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.

Authors:  Theodoros P Vassilakopoulos; Michail Michail; Sotirios Papageorgiou; Georgia Kourti; Maria K Angelopoulou; Fotios Panitsas; Sotirios Sachanas; Christina Kalpadakis; Eirini Katodritou; Theoni Leonidopoulou; Ioannis Kotsianidis; Eleftheria Hatzimichael; Maria Kotsopoulou; Maria Dimou; Eleni Variamis; Dimitrios Boutsis; Evangelos Terpos; Maria N Dimopoulou; Stamatios Karakatsanis; Eurydiki Michalis; George Karianakis; Pantelis Tsirkinidis; Chryssa Vadikolia; Christos Poziopoulos; Anna Pigaditou; Effimia Vrakidou; Theophanis Economopoulos; Lydia Kyriazopoulou; Marina P Siakantaris; Marie-Christine Kyrtsonis; Argyris Symeonidis; Konstantinos Anargyrou; Maria Papaioannou; Evdoxia Hatjiharissi; Elissavet Vervessou; Maria Tsirogianni; Maria Palassopoulou; Gabriella Gainaru; Ekaterini Stefanoudaki; Panayiotis Zikos; Panayiotis Tsirigotis; Gerasimos Tsourouflis; Theodora Assimakopoulou; Pavlina Konstantinidou; Helen A Papadaki; Katerina Megalakaki; Meletios-Athanasios Dimopoulos; Vassiliki Pappa; Themis Karmiris; Paraskevi Roussou; Panayiotis Panayiotidis; Kostas Konstantopoulos; Gerassimos A Pangalis
Journal:  Oncologist       Date:  2021-06-17

2.  Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.

Authors:  Theodoros P Vassilakopoulos; Sotirios G Papageorgiou; Maria K Angelopoulou; Sophia Chatziioannou; Vassilios Prassopoulos; Stamatios Karakatsanis; Maria Arapaki; Zois Mellios; Sotirios Sachanas; Christina Kalpadakis; Eirini Katodritou; Theoni Leonidopoulou; Ioannis Kotsianidis; Eleftheria Hatzimichael; Maria Kotsopoulou; Maria Dimou; Eleni Variamis; Dimitrios Boutsis; Evangelos Terpos; Evridiki Michali; George Karianakis; Pantelis Tsirkinidis; Chryssa Vadikolia; Christos Poziopoulos; Anna Pigaditou; Effimia Vrakidou; Marina P Siakantaris; Marie-Christine Kyrtsonis; Argyris Symeonidis; Konstantinos Anargyrou; Maria Papaioannou; Evdoxia Chatziharissi; Elissavet Vervessou; Maria Tsirogianni; Maria Palassopoulou; Gabriella Gainaru; Catherine Mainta; Panagiotis Tsirigotis; Theodora Assimakopoulou; Pavlina Konstantinidou; Helen Papadaki; Meletios-Athanassios Dimopoulos; Vassiliki Pappa; Themis Karmiris; Paraskevi Roussou; Ioannis Datseris; Panayiotis Panayiotidis; Kostas Konstantopoulos; Gerassimos A Pangalis; Phivi Rondogianni
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

3.  Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.

Authors:  Julien Lazarovici; Marie Terroir; Julia Arfi-Rouche; Jean-Marie Michot; Sacha Mussot; Valentina Florea; Maria-Rosa Ghigna; Peggy Dartigues; Cynthia Petrovanu; Alina Danu; Christophe Fermé; Vincent Ribrag; David Ghez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-21       Impact factor: 9.236

4.  Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Haematologica       Date:  2018-08       Impact factor: 9.941

5.  Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.

Authors:  T P Vassilakopoulos; S Papageorgiou; G A Pangalis; S Chatziioannou; M K Angelopoulou; P Panayiotidis; K Konstantopoulos; P Rondogianni
Journal:  Leukemia       Date:  2016-06-03       Impact factor: 11.528

6.  PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP.

Authors:  K Lontos
Journal:  Leukemia       Date:  2016-05-17       Impact factor: 11.528

7.  High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.

Authors:  Joanna Romejko-Jarosinska; Beata Ostrowska; Anna Dabrowska-Iwanicka; Katarzyna Domanska-Czyz; Grzegorz Rymkiewicz; Ewa Paszkiewicz-Kozik; Robert Konecki; Anna Borawska; Agnieszka Druzd-Sitek; Elzbieta Lampka; Wlodzimierz Osiadacz; Michal Osowiecki; Lidia Popławska; Monika Swierkowska; Lukasz Targonski; Joanna Tajer; Grazyna Lapinska; Malwina Smorczewska; Jan Walewski
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

8.  Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.

Authors:  Stamatis J Karakatsanis; Maria Bouzani; Argyris Symeonidis; Maria K Angelopoulou; Sotirios G Papageorgiou; Michail Michail; Gabriella Gainaru; Georgia Kourti; Sotirios Sachanas; Christina Kalpadakis; Eirini Katodritou; Theoni Leonidopoulou; Ioannis Kotsianidis; Eleftheria Hatzimichael; Maria Kotsopoulou; Maria Dimou; Eleni Variamis; Dimitrios Boutsis; Nick Kanellias; Maria N Dimopoulou; Evridiki Michali; George Karianakis; Pantelis Tsirkinidis; Chryssa Vadikolia; Christos Poziopoulos; Anna Pigaditou; Effimia Vrakidou; Theophanis Economopoulos; Lydia Kyriazopoulou; Marina P Siakantaris; Marie-Christine Kyrtsonis; Konstantinos Anargyrou; Maria Papaioannou; Evdoxia Hatjiharissi; Elissavet Vervessou; Maria Tsirogianni; Maria Palassopoulou; Ekaterini Stefanoudaki; Panayiotis Zikos; Panayiotis Tsirigotis; Gerassimos Tsourouflis; Theodora Assimakopoulou; Evgenia Verrou; Helen Papadaki; Polixeni Lampropoulou; Meletios-Athanasios Dimopoulos; Vassiliki Pappa; Kostas Konstantopoulos; Themis Karmiris; Paraskevi Roussou; Panayiotis Panayiotidis; Gerassimos A Pangalis; Theodoros P Vassilakopoulos
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

9.  Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy.

Authors:  Anna Kocurek; Bogdan Małkowski; Agnieszka Giza; Wojciech Jurczak
Journal:  Contemp Oncol (Pozn)       Date:  2016-09-05

10.  End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.

Authors:  Christopher Melani; Ranjana Advani; Mark Roschewski; Kelsey M Walters; Clara C Chen; Lucia Baratto; Mark A Ahlman; Milos D Miljkovic; Seth M Steinberg; Jessica Lam; Margaret Shovlin; Kieron Dunleavy; Stefania Pittaluga; Elaine S Jaffe; Wyndham H Wilson
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.